Open AccessEfficacy of tyrosine kinase inhibitors in routine clinical practice: Epidermal growth factor mutations and their implications
Author(s) -
Tanja Ovčariček,
Tanja Čufer,
Izidor Kern,
Eva Sodja,
Aleksander Sadikov
Publication year - 2013
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.113379
Subject(s) - kras , medicine , oncology , lung cancer , log rank test , mutation , epidermal growth factor receptor , tyrosine kinase , gene mutation , proportional hazards model , cancer , gene , biology , colorectal cancer , genetics , receptor
Activating mutations in the epidermal growth factor (EGFR) gene confer sensitivity to the tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). TKI treatment efficacy and EGFR mutation implications were evaluated in clinically selected advanced NSCLC patients treated with TKIs in routine clinical practice.